Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.39 USD
+0.05 (3.73%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $1.39 0.00 (0.00%) 4:42 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 11/12/24 |
---|---|
Current Quarter | -0.67 |
EPS Last Quarter | -0.66 |
Last EPS Surprise | -13.79% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -2.75 |
Next Year | -2.38 |
EPS (TTM) | -2.88 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.08M | 0.00M | 0.26M | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.67 | -0.69 | -2.75 | -2.38 |
# of Estimates | 1 | 1 | 1 | 1 |
Most Recent Consensus | -0.67 | -0.69 | -2.75 | -2.38 |
High Estimate | -0.67 | -0.69 | -2.75 | -2.38 |
Low Estimate | -0.67 | -0.69 | -2.75 | -2.38 |
Year ago EPS | -0.86 | -0.63 | -3.57 | -2.75 |
Year over Year Growth Est. | 22.09% | -9.52% | 22.97% | 13.45% |
Agreement - Estimate Revisions
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 1 | 1 | 1 | 1 |
Down Last 60 Days | 1 | 1 | 1 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.67 | -0.69 | -2.75 | -2.38 |
7 Days Ago | -0.67 | -0.69 | -2.75 | -2.38 |
30 Days Ago | -0.37 | -0.37 | -1.87 | -1.47 |
60 Days Ago | -0.37 | -0.37 | -1.87 | -1.47 |
90 Days Ago | -0.37 | -0.37 | -1.87 | -1.47 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.67 | -0.69 | -2.75 | -2.38 |
Zacks Consensus Estimate | -0.67 | -0.69 | -2.75 | -2.38 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (6/2024) |
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.66 | -0.73 | -0.63 | -0.86 | NA |
Estimate | -0.58 | -0.79 | -0.78 | -1.12 | NA |
Difference | -0.08 | 0.06 | 0.15 | 0.26 | 0.10 |
Surprise | -13.79% | 7.59% | 19.23% | 23.21% | 9.06% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more